HOOKIPA Pharma competitors

Richard A Miller is a co-founder, the president, and chief executive officer of [Corvus Pharmaceuticals](https://www.crunchbase.com/organization/corvus-pharmaceuticals#/entity), a clinical-stage biopharmaceutical company focused on the development of novel agents. Previously, he co-founded Pharmacyclics and served the same company as the chief executive officer. At Pharmacyclics, he led the initial discovery and development efforts for ibrutinib. Prior to co-founding Pharmacyclics, Miller co-founded IDEC and held various leadership roles as vice president and director at the same company. He has also founded other private and public biotech companies. Miller holds a Doctor of Medicine degree, summa cum laude, from the State University of New York Medical School and is currently Adjunct Clinical Professor of Medicine at Stanford University Medical Center.

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

John Kollins is a President/CEO/Co-Founder at SATSUMA PHARMACEUTICALS INC, Board Member at SATSUMA PHARMACEUTICALS INC, and Advisor at Covx and is based in South San Francisco, California. He has experience at ATHENA NEUROSCIENCES INC and Elan Pharmaceutical and has worked as Chief Operating Officer at Oxigene Inc, Vice President at SurroMed, and Advisor To CEO at SurroMed. John works or has worked as Consultant at Covx, CHAIRMAN at CovX Research LLC, and Consultant at Entelos. He studied at Duke University between 1981 and 1985 and University of Virginia Darden School of Business between 1987 and 1989.

David Arthur is a Chief Executive Officer at SALARIUS PHARMACEUTICALS, INC. and Board Member at SALARIUS PHARMACEUTICALS, INC. and is based in Wilton, Connecticut. He has worked as Managing Director at Dacon Pharma LLC, Process Improvement Engineer and Production Manager at Milliken & Co, and Business Development RTP N.C. at GSK. David studied at Fuqua School of Business between 1988 and 1990 and NC State University between 1980 and 1984.

Dr. Randall Schatzman, Ph.D., chief executive officer and board member, joined Bolt Biotherapeutics in 2019 with over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are now currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer reviewed scientific publications.